Media Center

31-08-2022

Mymetics and PCI Biotech sign a preclinical research collaboration

Epalinges, Switzerland, August 31, 2022, Mymetics Corporation (OTCQB: MYMX) a pioneer in the research and development of virosome based vaccines and immunotherapies against infectious and life disabling diseases, and PCI Biotech (OSE: PCIB), a Norwegian cancer focused biopharmaceutical company, have entered into a preclinical research collaboration with the aim to explore technological synergies for the possible enhancement of cancer therapy. The project is the first step in determining if there is a basis for a further collaboration between Mymetics and PCI Biotech, of short duration and without immediate commercial impact for either of the parties involved.

24-03-2022

Publication in "Nature–Scientific Reports"

Epalinges, Switzerland, March 24, 2022 - Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome based vaccines and immunotherapies against human life disabling and infectious diseases, announced today a publication in Nature Scientific Reports in collaboration with the AMC – Amsterdam University Medical Center, with title: “A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike”.

23-02-2022

Publication in "Frontiers in Immunology"

Epalinges, Switzerland, February 22, 2022 - Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome based vaccines and immunotherapies against human life disabling and infectious diseases, announced today a publication in Frontiers in Immunology with title: “Cooperation between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques against Mucosal SHIV challenges”

05-01-2021

Publication in "Clinical & Experimental Allergy"

Epalinges, January 5, 2021: Following two successful studies with its virosome platform, Mymetics announces the acceptance of its joint publication in the scientific journal Clinical & Experimental Allergy with Stallergenes Greer SA and Anergis SA, with the title: Bet v 1 contiguous overlapping peptides anchored to virosomes with TLR4 agonist enhance immunotherapy efficacy in mice.

09-12-2020

Publication in "nature.com/npjvaccines"

Epalinges, January 31, 2020: Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models

18-11-2020

Mymetics to advance Preclinical Studies for Virosome-based Covid-19 Vaccine through Innosuisse grant

Epalinges, Switzerland, November 18, 2020 – Mymetics SA, a subsidiary of Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, and Insel Gruppe AG, of which the Inselspital, Bern University Hospital, are part of, today announced that they have been awarded a grant from the Swiss Innovation Agency (Innosuisse). The grant will allow Mymetics in collaboration with the Department of Pneumology at the Inselspital, Bern University Hospital and the Department of Biomedical Research DBMR of Bern University to start a preclinical study which will investigate Mymetics’ virosome-based Covid-19 nasal vaccine candidate for safety and tolerance, and its capacity to elicit protective respiratory immunity to block nasal infection and virus spreading to the lungs and brain.

02-11-2020

Mymetics Starts Second Preclinical Study for Virosome-based Covid-19 vaccine

Epalinges, Switzerland, November 2, 2020 – Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today that it started a second preclinical study for its Covid-19 virosome-based vaccine candidates. The study is complementary to the one currently ongoing at Baylor College of Medicine in Texas, USA and is performed at the Helmholtz Center of Infection Research (HZI) in Germany.

23-09-2020

Mymetics Starts Preclinical Studies with Baylor College of Medicine for Virosome-based Covid-19 Vaccine

Epalinges, Switzerland, September 23, 2020 – Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today as part of the Research Agreement signed in May 2020 with Baylor College of Medicine and Texas Children’s Center for Vaccine Development, that Mymetics has piloted and successfully produced different virosome formulations which incorporate the SARS-CoV-2 recombinant protein. The Company has now shipped these formulations to Baylor College of Medicine where they will be tested and compared in a pre-defined preclinical model in accordance with the Research Agreement signed between the parties in May 2020. Results are expected in three months.

11-06-2020

Mymetics Receives Support for Virosome-based Covid-19 vaccine development from European Vaccine Infrastructure project (Transvac2)

Epalinges, Switzerland, June 11, 2020 – Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today that its subsidiary, Mymetics SA, has received the confirmation to receive access to the European vaccine infrastructure TRANSVAC2 services for the evaluation and development of virosome-based vaccines against Covid-19, the disease caused by SARS-CoV-2.

28-05-2020

Mymetics Reports Successful Preclinical Study Results with COP-Virosomes as Second-Generation Allergy Immunotherapy

EPALINGES, Switzerland, May 28, 2020 – Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines and immunotherapies against life threatening and life disabling diseases, announced today that Stallergenes Greer, a worldwide leader in allergen immunotherapy (AIT) and Anergis, a leader in ultra-fast AIT research and development, reported the results of a joint research study evaluating the effects of the second generation Contiguous Overlapping Peptides (COP) allergen immunotherapy in a therapeutic model of birch allergy, with the aim of shortening the AIT administration schemes.

25-05-2020

Exploratory project to compare IO Biotech antigens linked to Mymetics’ virosomes in a preclinical tumor model

Epalinges, Switzerland, May 25, 2020 – Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines, announced today that Mymetics BV, the Dutch subsidiary of Mymetics Corporation, will start a research project with IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win® technology.

18-05-2020

Mymetics and Baylor College of Medicine start Research Collaboration for Virosome-based Covid-19 Vaccines

Epalinges, Switzerland, May 18, 2020 – Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today that its subsidiary, Mymetics BV, has signed a Research Collaboration Agreement with Baylor College of Medicine and Texas Children’s Center for Vaccine Development for evaluating their rationally designed recombinant protein-based SARS-CoV and SARS-CoV-2 antigens and combining them with Mymetics’ virosomes for the development of a safe and effective Covid-19 vaccine.

18-05-2020

Mymetics announces publication in npj - Vaccines “New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes”

Epalinges, Switzerland, 18 May 2020 – Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome based vaccines and immunotherapies against human life disabling and infectious diseases, announced today a publication in Nature Partner Journals “Vaccines” describing the results from a new GMP manufacturing process to obtain thermostable HIV-1 gp41 virosome vaccines under solid forms and various mucosal vaccination routes

03-02-2020

Mymetics announces publication in npj –Vaccines: “Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models

Epalinges, Switzerland, 3 February 2020 – Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome based vaccines and immunotherapies against human life disabling and infectious diseases, announced today that results from a study at the Swiss Tropical and Public Health Institute (Swiss TPH) were published on January 31, 2020 in the Nature Partner Journal (npj) Vaccines.

17-10-2019

Mymetics Announces New Study to Predict Efficacy of Second-Generation COP Allergy Immunotherpy with Virosomes

EPALINGES, Switzerland, October 17th, 2019 -The second-generation Allergen Immunotherapy based on Anergis Continuous Overlapping Peptides (COP) linked to Mymetics Virosomes will be tested by Stallergenes Greer using its therapeutic model of birch allergy -Results of the study are expected in Q1 2020

05-09-2019

MODERN VACCINES ADJUVANTS & DELIVERY SYSTEMS

9-11 September 2019, Inselspital, Universitatsspital, Bern, Switzerland

18-06-2019

World Vaccine Congress Europe 2019

29-31 October 2019, Palau de Congressos de Catalunya, Barcelona, Spain

18-06-2019

19th Annual Biotech in Europe Forum

25-26 September 2019, Congress Center, Basel, Switzerland

29-04-2019

Mymetics Receives Funding from NIH for Novel HIV Vaccine Study

Epalinges, Switzerland, April 29, 2019 – Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today that the National Institutes of Health (NIH) has awarded Mymetics and Texas Biomedical Research Institute (Texas Biomed) a five-year grant for the project called “Cold Chain-independent, Needle-free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels”.

25-04-2019

WORLD MALARIA DAY

Epalinges, Switzerland, April 25, 2019 – Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling human diseases has learned that there is inaccurate information in the public domain. Mymetics is dedicated to develop vaccines for life threatening and disabling diseases based on our virosome virus like particle platform.

06-03-2019

Malaria Vaccines for the World

8-10 May 2019, University of Oxford, Oxford, UK

13-12-2018

Mymetics Virosomes Successful in Allergy Proof-of-Concept Study

Epalinges, Switzerland, December 13, 2018 – Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today that the pre-clinical proof-of-concept study for allergies, with their partner Anergis SA, has met the success criteria.

14-11-2018

Mymetics presents new data regarding cold chain independent virosome based vaccines

Epalinges, Switzerland, 14 November 2018 – Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announces that new data is presented today by Mymetics at the annual Mucosal Vaccines, Adjuvants and Delivery meeting in Lausanne, Switzerland.

30-10-2018

New Mymetics data to be presented by LMIV at American Society of Tropical Medicine and Hygiene

Epalinges, Switzerland, 30 October 2018 – Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases announces that new data will be presented at the 67th American Society of Tropical Medicine and Hygiene (ASTMH), held from October 28 - November 1, 2018 at in New Orleans, Louisiana

16-10-2018

Mymetics Starts Research Collaboration Project in Cancer Immunotherapy with eTheRNA

Epalinges, Switzerland, October 16, 2018 – Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines, announced today that Mymetics BV, the Dutch subsidiary of Mymetics Corporation, has entered into a research collaboration project with eTheRNA immunotherapy NV, a clinical stage biotech company developing novel mRNA cancer immunotherapies.

12-10-2018

New Mymetics data regarding cold chain independent virosome based vaccines to be presented at AAPS in Washington, D.C.

Epalinges, Switzerland, 11 October 2018 – Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announces that new data will be presented by Mymetics’ partner, Upperton Ltd., at the American Association of Pharmaceutical Scientists Annual Meeting in Washington, D.C., on November 5th-7th, 2018.

26-07-2018

Material Incorrect Information in Public Domain

Epalinges, Switzerland, July 26, 2018 - Material Incorrect Information in Public Domain

03-07-2018

19th Annual World Vaccine Congress Europe 2018

29th - 31st October 2018, EPIC SANA Lisbon, Portugal

03-07-2018

18th Annual Biotech in Europe Forum for Global Partnering and Investment

4th – 5th October 2018, Congress Center Basel, Switzerland

01-07-2018

Virus-Like Particle & Nano-Particle Vaccines

25-27 September 2018, Inselspital, Universitatsspital, Bern, Switzerland

26-06-2018

Development of a Virosomal RSV Vaccine Containing 3D-PHAD® Adjuvant: Formulation, Composition, and Long-Term Stability

June 26th, 2018 - Characterization of virosomes, in late stage preclinical development as vaccines for Respiratory Syncytial Virus (RSV), with a membrane-incorporated synthetic monophosphoryl lipid A, 3D-PHAD® adjuvant.

07-05-2018

MACIVIVA Report Summary

Periodic Reporting for period 2 - MACIVIVA (MAnufacturing process for Cold-chain Independent VIrosome-based VAccines)

25-04-2018

6th Modern Vaccines Adjuvants Formulation, 2nd-4th May 2018, Leiden, NL

2nd-4th May 2018, LUMC – Leiden University Medical Center, Leiden, The Netherlands

23-04-2018

Anergis and Mymetics Start Research Collaboration Project on the use of Virosomes for Ultra-Fast Allergy Immunotherapy

Epalinges, Switzerland, April 23, 2018 – Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines, and Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, announced today that Mymetics SA, the Swiss subsidiary of Mymetics Corporation and Anergis SA have entered into a Research Collaboration project.

08-01-2018

World Vaccine congress, 10-12 October 2017, Barcelona.

Copy of presentation at World Vaccine Congress, 10th-12th October 2017 in Barcelona, Spain

13-09-2017

Mymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines

Epalinges, September 13, 2017 – Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that they will present new preclinical data. The new data demonstrates that nasal powder, oral capsules and sublingual tablets developed by MACIVIVA partners, containing Mymetics HIV-1 virosome based vaccine candidate, could induce specific antibody immune response in rodent and mini-pig animal models.

05-09-2017

17th Annual BIOTECH in Europe Forum, 26-27 September 2017, Basel

26th-27th September 2017, Congress Center Basel, Switzerland

05-09-2017

ILS Liposome Advances and Liposome Research Days Combined Conference, 16-18 September 2017, Athens

16th-18th September 2017, Royal Olympic Hotel, Athens

10-03-2017

MACIVIVA Report Summary

Periodic Reporting for period 1 - MACIVIVA (MAnufacturing process for Cold-chain Independent VIrosome-based VAccines)

03-03-2017

Modern Vaccines Adjuvants & Delivery Systems, 12-14 September 2017, Crowne Plaza Hotel, Porto, Portugal

03-03-2017

Influenza Vaccines for the World: 19-21 April 2017, CHUV/UNIL, Lausanne, Switzerland

03-03-2017

10th Annual European Life Sciences CEO Forum & Exhibition, March 6 – 7, Hilton Zurich Airport, Switzerland

01-12-2016

Mymetics Starts Research Project with Sanofi for Influenza Vaccines

Epalinges, December 1, 2016 Mymetics Corporation (MYMX), a pioneer and leader in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that its subsidiary Mymetics B.V. has agreed on a research project with Sanofi Pasteur, the vaccine division of Sanofi (SNY).

20-09-2016

Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development

Epalinges, September 19, 2016 Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today the continuation of the collaboration with the Texas Biomedical Research Institute related to the Mymetics' HIV vaccine candidate.

29-08-2016

World Vaccine Congress in Barcelona, 10 – 12 October, 2016

29-08-2016

Biotech in Europe Annual Investor Forum in Basel, 27 – 28 September, 2016

29-08-2016

Mucosal Vaccines, Adjuvants and Delivery Congress in Lausanne, 14 – 16 September, 2016

29-08-2016

Vaccine Congress in the Netherlands on September 4-7, 2016

11-04-2016

Mymetics’ HIV vaccine candidate confirms promise in preclinical study with the Texas Biomedical Research Institute

Epalinges, April 11 2016 – Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate has shown to generate significant protection in groups of twelve female monkeys against repeated AIDS virus exposures during part of the preclinical study.

05-04-2016

Mymetics announces successful preclinical results with malaria transmission-blocking vaccine candidate

Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome based vaccines to prevent transmission of human infectious diseases, announced today that the preclinical study with Mymetics’ virosome based formulations for a malaria transmission-blocking vaccine candidate has been successful. The study showed that the virosome vaccine candidates, at the highest dose tested, generate high antibody titers against the required antigens and they were able to significantly reduce (97-100%) the transmission of the Plasmodium falciparum parasite.

03-03-2016

Virus-Like Particle & Nano-Particle Vaccines in Leiden, The Netherlands, on June 22nd - 24th

03-03-2016

Malaria Vaccines for the World in Leiden, The Netherlands, on May 2nd - 4th

03-03-2016

European Life Science CEO forum in Zurich on March 15th – 16th

29-01-2016

Mymetics announces discontinuation of the RSV collaborative project

Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that its subsidiary Bestewil Holding BV, has received notice from RSV Corporation (RSVC) that it will no longer pursue the development of a vaccine technology for Respiratory Syncytial Virus (RSV) in order to focus on other infectious thérapies. On December 27, 2013, Mymetics and RSVC, funded by Astellas Pharma Inc., had announced the signature of a License and Collaborative Agreement focusing on RSV, which will now formally be terminated as of July 25, 2016.

29-12-2015

Biotech Showcase in San Francisco on January 11th - 13th

30-10-2015

World Vaccine Congress in Madrid on Nov 9th -11th

Glad to announce that Mymetics will present on the World Vaccine Congress in Madrid on Nov 9th -11th

11-10-2015

Particle based platforms for malaria vaccines

December 22nd, 2015 - Particle based malaria vaccines

20-04-2015

Mymetics-led consortium awarded € 8.4 million for development of thermo stable and cold-chain independent vaccines

Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that its subsidiary Mymetics BV in the Netherlands is leading a consortium that has been selected to receive project grants with a total value of €8.4 million. A total of €5.3 million is funded as part of Horizon 2020, the European Union research and innovation framework program and up to €3.1 million of funding will be provided by the Swiss State Secretariat for Education, Research and Innovation (SERI) for the Swiss based consortium partners. The grants will fund the evaluation, development and manufacturing scale-up of thermo stable and cold-chain independent nano-pharmaceutical virosome-based vaccine candidates.

18-11-2014

Mymetics announces new collaboration to advance the development of an innovative Malaria vaccine candidate

Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that the PATH Malaria Vaccine Initiative (MVI) has chosen Mymetics to develop and produce virosome based vaccine formulations for a malaria transmissionblocking vaccine candidate. MVI is a global program whose objective is to accelerate the development of malaria vaccines and catalyze timely access in endemic countries.

29-09-2014

Mymetics’ promising HIV vaccine candidate obtains funding to begin study at Texas Biomedical Research Institute

Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate will enter a new preclinical trial to confirm excellent results obtained in a previous trial.

16-07-2014

Mymetics Signs Agreement to Manufacture Virosome based HER-Vaxx Cancer Immunotherapy

Mymetics (OTC BB: MYMX) announced today that it has signed an exclusive agreement with Imugene (ASX; IMU), an Australian based biopharmaceutical company, to manufacture and develop its cancer immunotherapy HER-Vaxx, which is planned to enter into a PhaseI/II clinical trial in 2015.

10-03-2014

Mymetics strengthens virosome vaccine platform

Mymetics announced today that it has secured and further strengthened its know-how and leadership in the research and development of virosome based vaccines as well in manufacturing and IP.

06-01-2014

ASTELLAS TO FORM STRATEGIC PARTNERSHIP WITH CLEARPATH TO BUILD VACCINE PORTFOLIO

Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic partnership to form a portfolio of development companies focused on vaccines targeting infectious diseases. The partnership was established to support Astellas’ goal of building a global vaccine franchise and launched its first company, RSV Corporation (RSVC), in December 2013. Astellas will fund RSVC’s development of a virosome vaccine technology, licensed from Mymetics Corporation (Mymetics ‐ OTC BB: MYMX), for respiratory syncytial virus (RSV) through completion of a Phase 2b human proof‐of‐concept study. Based on the strategic partnership, Astellas received exclusive rights to acquire RSVC as well as further develop and commercialize the vaccine product.

10-04-2013

A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats

Respiratory syncytial virus (RSV) has been recognized as an important vaccine target for over 60 years; however, there is no vaccine on the market today.

13-03-2013

Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats

Respiratory syncytial virus infection remains a serious health problem, not only in infants but also in immunocompromised adults and the elderly. An effective and safe vaccine is not available due to several obstacles: non-replicating RSV vaccines may prime for excess Th2-type responses and enhanced respiratory disease (ERD) upon natural RSV infection of vaccine recipients.

21-02-2013

Data published in PLOS ONE show Mymetics’ HIV-1 Innovative vaccine is safe and elicits strong immunogenicity

Results from a randomized study published in PLOS ONE1 today demonstrate that Mymetic’ innovative HIV-1 (Human Immunodeficiency Virus type 1) vaccine is safe and well tolerated and demonstrates a high level of immunogenicity in a Phase I trial involving 24 healthy women. The publication highlights that vaccine-induced mucosal antibodies may contribute to reduce sexually transmitted HIV-1. Mymetics Corporation is a pioneer in the development of vaccines that use the human mucosal system, the body’s first line of defense, to prevent transmission of infectious diseases.

12-02-2013

Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes

The human immunodeficiency virus type 1 (HIV-1) is mainly transmitted through sexual contact. To infect its host, HIV-1 employs its viral membrane surface trimeric envelope glycoprotein, composed of the receptor binding domain gp120 and the membrane anchored fusion protein subunit gp41.

27-11-2012

Mymetics announces change of Directors and management

Mymetics Corporation, a pioneer in the development of vaccines that use the human mucosal system, the body’s first line of defense, to prevent transmission of infectious diseases, announced today the appointment of Ronald Kempers, currently CFO and COO, as President and CEO of Mymetics Corporation effective November 19, 2012. He replaces Dr. Christopher S. Henney and Grant Pickering who had been respectively appointed on March 22, 2012 as director and Chairman of the Board of Directors and as a director and President and Chief Executive Officer to pursue new strategic directions, including the potential change of Mymetics' location from Switzerland to the United States.

15-05-2012

Immunogenicity and Protective Capacity of a Virosomal Respiratory Syncytial Virus Vaccine Adjuvanted with Monophosphoryl Lipid A in Mice

Respiratory Syncytial Virus (RSV) is a major cause of viral brochiolitis in infants and young children and is also a significant problem in elderly and immuno-compromised adults.

06-04-2012

Mymetics Appoints Grant Pickering CEO and Christopher Henney Chairman

Mymetics Corporation, a leader in the development of mucosal and virosomal-based vaccines for infectious diseases, announced today the appointment of Grant E. Pickering as President and Chief Executive Officer of Mymetics Corporation and the election of Dr. Christopher S. Henney as Chairman of the Board of Directors. Mymetics further announced the appointments of Ulrich Burkhard and Mr. Pickering to its Board of Directors. These changes are made in connection with the efforts of Mymetics to obtain additional financing and to advance the development of its vaccine platform.

04-10-2011

Mymetics reclaims innovative intra-nasal influenza vaccine

Mymetics Corporation, a pioneer in the development of vaccines that use the human mucosal system, the body’s first line of defense, to prevent transmission of infectious diseases, announced today that it has been able to regain its innovative intra-nasal influenza vaccine from Solvay.

04-07-2011

Virosome-Formulated Plasmodium falciparum AMA-1 & CSP Derived Peptides as Malaria Vaccine: Randomized Phase 1b Trial in Semi-Immune Adults & Children

The development of an effective malaria vaccine is regarded as one cornerstone in the fight against this deadly disease and to achieve its eventual elimination.

26-05-2011

Mymetics Realizes Successful Phase I Study with Its Innovative HIV Vaccine MYM-V101

Mymetics Corporation, a pioneer in the development of vaccines that use the human mucosal system, the body’s first line of defense, to prevent transmission of infectious diseases, announced today that its innovative HIV-1 (Human Immunodeficiency Virus type 1) vaccine proved to be safe and well tolerated and demonstrated a high level of immunogenicity in a Phase I trial involving 24 healthy women.

25-02-2011

Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges

Human immunodeficiency virus (HIV)-1 is mainly transmitted mucosally during sexual intercourse. We therefore evaluated the protective efficacy of a vaccine active at mucosal sites.

15-02-2011

Mymetics publishes data from groundbreaking HIV vaccine study

Mymetics Corporation, a pioneer in the development of vaccines preventing mucosal transmission of human infectious diseases, announced today that a paper describing detailed results of a successful preclinical trial on its innovative HIV-1 (Human Immunodeficiency Virus type 1) vaccine was recently published in the leading scientific journal Immunity.

30-11-2010

Mymetics HIV Vaccine Shows Strong Preliminary Phase I Data

Mymetics Corporation (OTCBB: MYMX), a pioneer in the development of vaccines preventing mucosal transmission of human infectious diseases, announced today strong preliminary results of a Phase I trial on its promising HIV vaccine, MYMV101. Unlike most current vaccines, seeking to eliminate pathogens once they have already entered the bloodstream, Mymetics’ vaccines are designed to block early transmission and infection events, preventing virus from settling and spreading within the body. This represents a highly promising but, until now, poorly investigated approach to preventing HIV infection.

29-11-2010

Mymetics Secures New Patent for Virosome based Vaccines

Mymetics Corporation (OTCBB: MYMX), a pioneer in the development of vaccines preventing early transmission of human infectious diseases, announced today that the United States Patent and Trademark Office has issued a notice of allowance for the patent application “Phospholipid Virosome” # 10/544,939, based on WO 04/071492.